GlassScriptPhysician profile
Michael Arya Daneshvar
NPI 1194103861
$49,416.07
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.40 · 2022: $1,634 · 2023: $2,621 · 2024: $29K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Education: $12K · Travel and Lodging: $9,464 · Food and Beverage: $6,580 · Honoraria: $1,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $330 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,987.50 |
| Education | $11,802.81 |
| Travel and Lodging | $9,464.42 |
| Food and Beverage | $6,579.57 |
| Honoraria | $1,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $330.00 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,677.02 | 2023-2025 | Da Vinci Surgical System |
| Koelis INC. | $14,398.32 | 2022-2025 | |
| Pfizer INC. | $3,840.00 | 2025 | |
| Histosonics, INC. | $2,931.74 | 2024 | |
| Janssen Biotech, INC. | $2,200.47 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Angiodynamics, INC. | $1,539.48 | 2022-2025 | Nanoknife |
| Immunitybio, INC. | $1,500.00 | 2024 | |
| F. Hoffmann-La Roche Ag | $1,153.27 | 2024 | |
| Janssen Scientific Affairs, LLC | $450.50 | 2023-2025 | Erleada |
| Astrazeneca Pharmaceuticals LP | $413.86 | 2023-2025 | Lynparza |
| Boston Scientific Corporation | $279.76 | 2023-2025 | Spaceoar Vue System - 10ml |
| Edap Technomed INC | $216.00 | 2024 | |
| Dendreon Pharmaceuticals LLC | $205.85 | 2023-2025 | Provenge |
| Astellas Pharma US INC | $200.59 | 2025 | Padcev, Xtandi |
| Urogen Pharma, INC. | $199.11 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $187.50 | 2025 | Surseal II |
| Blue Earth Diagnostics | $172.80 | 2024-2025 | Posluma |
| Bayer Healthcare LLC | $149.78 | 2025 | |
| Progenics Pharmaceuticals, INC. | $140.24 | 2023 | Pylarify |
| Calyxo, INC. | $124.74 | 2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $124.46 | 2023 | Lynparza |
| Cook Medical LLC | $95.40 | 2020 | |
| Tolmar, INC. | $57.45 | 2025 | Eligard, Rubraca, Jatenzo |
| Fennec Pharmaceuticals, INC. | $50.81 | 2024 | Pedmark |
| Pharmaand Gmbh | $46.91 | 2025 | Rubraca |
| Ferring Pharmaceuticals INC. | $41.32 | 2024-2025 | Adstiladrin |
| Teleflex LLC | $18.69 | 2025 | Barrigel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daneshvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.